# Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

Study · id `cardio:ct-nct02145104` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02145104](<https://clinicaltrials.gov/study/NCT02145104>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02145104

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

## Technical summary

Registry record NCT02145104. Randomized; double masking; primary purpose treatment. Start 2014-06-17 (actual); primary completion 2016-06-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 286 participants (enrolled count; ClinicalTrials.gov record NCT02145104, source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)
- Started: 2014-06-17 (actual) (ClinicalTrials.gov record NCT02145104, source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)
- Primary completion: 2016-06-07 (actual) (ClinicalTrials.gov record NCT02145104, source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)
- Completion: 2016-09-29 (actual) (ClinicalTrials.gov record NCT02145104, source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02145104, source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02145104-2018-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
- Condition: Hypertension
- Intervention (Drug): valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
- Lead sponsor: IlDong Pharmaceutical Co Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: IlDong Pharmaceutical Co Ltd (`cardio:org-ildong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 11c5ff9d1b74e2f3c63fbe4c43bad2d68646b32fe091689e5418b2e66c992360
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
